by Barry101 | May 6, 2019 | Press Release
OCALA, Fla., May 06, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases – and whose product portfolio...
by Barry101 | Apr 30, 2019 | Press Release
OCALA, Fla., April 30, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today significant progress in its Ampligen...
by Barry101 | Apr 25, 2019 | Press Release
OCALA, Fla., April 25, 2019 — Hemispherx Biopharma Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, announced today that CEO Thomas K. Equels will present at the Planet MicroCap Showcase...
by Barry101 | Apr 22, 2019 | Press Release
OCALA, Fla., April 22, 2019 — (NYSE American: HEB) – Hemispherx Biopharma, Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced the appointment of Ellen Lintal as the...
by Barry101 | Apr 2, 2019 | Press Release
OCALA, Fla., April 02, 2019 — (NYSE American: HEB) – Hemispherx today announced active initiation of a clinical trial sponsored by Roswell Park Comprehensive Cancer Center (Roswell Park) in Buffalo, N.Y. evaluating Hemispherx’ experimental drug...
by Barry101 | Apr 1, 2019 | Press Release
OCALA, Fla., April 01, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) announces financial results for the fiscal year ended December 31, 2018, and provides a business update.Highlights of 2018 included:Publication of a non-clinical study showing Ampligen...
